Key result
Higher Penn-Columbia score linked to ~38% higher 1-year mortality per point in LVAD patients.
Why the study?
Previously developed scoring systems for predicting outcomes after continuous flow LVAD implantation are limited to past device eras or specific devices, necessitating a new risk model based on current preimplant variables.
Does the Penn-Columbia Risk Score predict 1-year survival in patients treated with continuous flow LVAD?
Cohort (n=470)
Yes
Does the Penn-Columbia Risk Score predict 1-year survival in patients treated with continuous flow LVAD?
Hazard Ratio: 1.38
p-value: p=0.004
The Penn-Columbia Risk Score successfully predicts 1-year mortality in patients receiving continuous flow LVADs, aiding in appropriate patient selection.
New preimplant LVAD risk model may refine candidate selection; leaves open need for prospective validation before adoption.
Background Predicting which patients are unlikely to benefit from continuous flow left ventricular assist device (LVAD) treatment is crucial for the identification of appropriate patients. Previously developed scoring systems are limited to past eras of device or restricted to specific devices. Our objective was to create a risk model for patients treated with continuous flow LVAD based on the preimplant variables. Methods and Results We performed a retrospective analysis of all patients implanted with a continuous flow LVAD between 2006 and 2014 at the University of Pennsylvania and included a total of 210 patients (male 78%; mean age, 56±15; mean follow‐up, 465±486 days). From all plausible preoperative covariates, we performed univariate Cox regression analysis for covariates affecting the odds of 1‐year survival following implantation ( P <0.2). These variables were included in a multivariable model and dropped if significance rose above P =0.2. From this base model, we performed step‐wise forward and backward selection for other covariates that improved power by minimizing Akaike Information Criteria while maximizing the Harrell Concordance Index. We then used Kaplan–Meier curves, the log‐rank test, and Cox proportional hazard models to assess internal validity of the scoring system and its ability to stratify survival. A final optimized model was identified based on clinical and echocardiographic parameters preceding LVAD implantation. One‐year mortality was significantly higher in patients with higher risk scores (hazard ratio, 1.38; P =0.004). This hazard ratio represents the multiplied risk of death for every increase of 1 point in the risk score. The risk score was validated in a separate patient cohort of 260 patients at Columbia University, which confirmed the prognostic utility of this risk score ( P =0.0237). Conclusion We present a novel risk score and its validation for prediction of long‐term survival in patients with current types of continuous flow LVAD support.
No takes yet. Share an insight, caveat, or question.
Birati et al. (2018) conducted a cohort in Continuous flow left ventricular assist device (LVAD) treatment (n=470). Penn-Columbia Risk Score vs. Lower risk score (per 1-point increase) was evaluated on 1-year mortality (HR 1.38, p=0.004). The Penn-Columbia risk score significantly predicted 1-year mortality in patients with continuous flow LVADs, with a 1.38-fold increased risk of death for every 1-point increase in the score (P=0.004).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: